Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
60S ribosomal protein L6 (RPL6)
- Target
- RPL6
- Molecular classification
- Ribosomal protein, Structural constituent of ribosome, Other (not a receptor, enzyme, transporter, etc.)
01
Overview
60S ribosomal protein L6 (RPL6) is a highly conserved structural protein of the large (60S) eukaryotic ribosomal subunit. It participates in the assembly and function of ribosomes, thus enabling cellular protein synthesis. Besides its main role in the ribosome, RPL6 can bind to the tax-responsive enhancer element of human T-cell leukemia virus type 1 (HTLV-I), potentially modulating transcriptional activity. Its gene is found on chromosome 12q24.1, a region associated with Noonan syndrome, suggesting possible disease relevance, though direct mechanistic links remain under investigation. No specific drugs target RPL6, and it is not a recognized therapeutic target. Its disruption may impair ribosome biogenesis and cell viability.
- Other names
- Large ribosomal subunit protein eL6RPL6TXREB1TaxREB107TAXREB107L6eL660S ribosomal protein L6Neoplasm-related protein C140Tax-responsive enhancer element-binding protein 107SHUJUN-2DNA-binding protein TAXREB107
02
Mechanism of action
No documented mechanisms of direct pharmacological modulation; mechanisms relate to its roles in ribosome function and potential DNA binding
03
Biological functions
Component of the large ribosomal subunit (60S), involved in the synthesis of proteins (translation)RNA bindingMay participate in tax-mediated transactivation of transcription via binding to the tax-responsive enhancer of HTLV-ISuppresses E3 ubiquitin ligase activity of HDM2, attenuating HDM2-mediated p53 ubiquitinationAlternative splicing is observed but encodes the same protein
04
Disease associations
Noonan syndrome (gene is mapped to a critical region associated with Noonan syndrome, but direct causality is not established)T-cell acute lymphoblastic leukemia (implicated via transcriptional activity modulation)Potential link to cancer via interaction with p53 pathwayOther: neoplasm relevance suggested by alias and binding properties
05
Safety considerations
Not applicable for direct targeting; however, global ribosomal protein deficiencies could impair protein synthesis and cause cellular dysfunction, potentially yielding abnormal cell phenotypes or contributing to diseaseDrugs inadvertently affecting ribosome proteins could result in cytotoxicity.
06
Biomarkers
Currently, RPL6 is not established as a clinically actionable biomarker for therapy selection or monitoringIts role in Noonan syndrome and leukemia is primarily associative.
Beyond the preview
Go deeper on 60S ribosomal protein L6 (RPL6).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 60S ribosomal protein L6 (RPL6).